BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35682939)

  • 21. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
    Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
    Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardioprotective effects of corilagin on doxorubicin induced cardiotoxicity via P13K/Akt and NF-κB signaling pathways in a rat model.
    Huang J; Lei Y; Lei S; Gong X
    Toxicol Mech Methods; 2022 Feb; 32(2):79-86. PubMed ID: 34369273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
    Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unraveling the biomechanistic role of Rac1/TWEAK/Fn14/NF-κB intricate network in experimentally doxorubicin-induced cardiotoxicity in rats: The role of curcumin.
    Soliman NA; Abo El Gheit RE; Abdel Ghafar MT; AbuoHashish NA; Ibrahim MAA; Abo Safia HS; El-Saka MH; Elshamy AM
    J Biochem Mol Toxicol; 2021 Aug; 35(8):e22829. PubMed ID: 34047412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MD-1 Deficiency Accelerates Myocardial Inflammation and Apoptosis in Doxorubicin-Induced Cardiotoxicity by Activating the TLR4/MAPKs/Nuclear Factor kappa B (NF-κB) Signaling Pathway.
    Zhang YJ; Huang H; Liu Y; Kong B; Wang G
    Med Sci Monit; 2019 Oct; 25():7898-7907. PubMed ID: 31636246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liquiritigenin-Loaded Submicron Emulsion Protects Against Doxorubicin-Induced Cardiotoxicity via Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Activity.
    Shi C; Wu H; Xu K; Cai T; Qin K; Wu L; Cai B
    Int J Nanomedicine; 2020; 15():1101-1115. PubMed ID: 32110010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic development and current uses of BCL-2 inhibition.
    Roberts AW
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):1-9. PubMed ID: 33275682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
    Crombie J; Davids MS
    Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baicalein alleviates doxorubicin-induced cardiotoxicity via suppression of myocardial oxidative stress and apoptosis in mice.
    Sahu BD; Kumar JM; Kuncha M; Borkar RM; Srinivas R; Sistla R
    Life Sci; 2016 Jan; 144():8-18. PubMed ID: 26606860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of cyclophosphamide-induced cardiotoxicity by methyl palmitate.
    El-Agamy DS; Elkablawy MA; Abo-Haded HM
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):399-409. PubMed ID: 28130575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
    Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-caryophyllene, a dietary phytocannabinoid attenuates oxidative stress, inflammation, apoptosis and prevents structural alterations of the myocardium against doxorubicin-induced acute cardiotoxicity in rats: An in vitro and in vivo study.
    Al-Taee H; Azimullah S; Meeran MFN; Alaraj Almheiri MK; Al Jasmi RA; Tariq S; Ab Khan M; Adeghate E; Ojha S
    Eur J Pharmacol; 2019 Sep; 858():172467. PubMed ID: 31216443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.
    Nguyen LXT; Troadec E; Kalvala A; Kumar B; Hoang DH; Viola D; Zhang B; Nguyen DQ; Aldoss I; Ghoda L; Budde E; Pichiorri F; Rosen S; Forman SJ; Marcucci G; Pullarkat V
    J Cell Physiol; 2019 Aug; 234(8):14040-14049. PubMed ID: 30623427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
    Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
    Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
    Choi JH; Bogenberger JM; Tibes R
    Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospects for Venetoclax in Myelodysplastic Syndromes.
    Garcia JS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.